Palivizumab does not improve long-term outcomes in kids with cystic fibrosis - Healio
Palivizumab does not improve long-term outcomes in kids with cystic fibrosis Healio
Palivizumab — a monoclonal antibody that prevents respiratory syncytial virus, or RSV, in high-risk infants — did not improve long-term outcomes like respiratory ...
Comments
Post a Comment